With the psychiatric side effects of rimonabant (sold as Acomplia in Europe and as Zimulti elsewhere) turning out to be even worse than originally thought, and the effectiveness of this new weight loss drug turning out to be pretty minimal, Sanofi-Aventis has yanked it from the market following a decision by European regulators to suspend marketing approval.

The shocking mortality rate for anorexia — higher than for any other psychiatric disorder — is not due just to starvation or physical deterioration, says new research, but to sufferers committing suicide in the most violent and determined of ways.